Physician profile
Mattison Perez
NPI 1003285560
$8,479.38
in general payments reported to CMS, 2019-2025
36 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,959 · 2022: $1,952 · 2023: $2,071 · 2024: $2,056 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,526.67 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,504.87 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,088.16 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $947.20 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $794.28 | 2021-2025 | Spravato, Xarelto |
| Abbvie INC. | $767.30 | 2021-2025 | |
| Pfizer INC. | $437.50 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.61 | 2021-2024 | Xifaxan |
| Tris Pharma INC | $236.96 | 2023-2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $229.70 | 2022-2024 | Abilify Maintena, Rexulti |
| Amgen INC. | $228.63 | 2022-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.31 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $220.67 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.43 | 2021-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $169.68 | 2021-2025 | Zoryve |
| Almatica Pharma LLC | $159.58 | 2022-2024 | Loreev Xr, Gralise |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mattison Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.